As a less expensive test to distinguish between LC and BLD in general practice clinics, the combination of four serum biomarkers (CYFR21, CEA, NSE, and SCC) seems more promising for the diagnosis of lung cancer and should be used in common practice. This evidence concerns the gene ENO2 and laryngotracheoesophageal cleft.